Gene name: | NDRG1 |
Aging type: | Prevent |
Aging characteristic: |
Tissue type: | -- |
Cell name: | HepG2 |
Gene ID: | 10397 |
Category: | protein coding |
Phenotype: | Hepatocellular carcinoma |
Experimental category: | HL |
PMID: | 24302615 |
Experiment: | SA-β-gal activity assay//Knockdown |
Description: | A large percentage (about 80%) of HepG2 cells transfected with NDRG1-specific siRNA was positive for SA-β-Gal staining. |
Regulatory pathway: | GSK3β-P53/-P16 |
R-AG-Pathway: | -- |
Official symbol(s): | GSK3B-TP53-CDKN2A |
Pathway experiment: | SA-β-gal activity assay//Western blot |
Pathway description: | The percentage of SA-β-Gal positive cells was also reduced in HepG2 cells co-transfected with NDRG1-specific siRNA and siRNA against p53, p16, p53 & p16, or GSK-3. Western blot results indicated that co-transfection of NDRG1-specific siRNA and siRNA against p53, p16, or p53 & p16 increased p-Rb level which was decreased by NDRG1-specific siRNA . Additionally, GSK-3β siRNA decreased GSK-3β, GSK-3β 9ser, p53, p21 and p16 levels, indicating that GSK-3β can stabilize p53 and p16 levels in HepG2 cells with NDRG1 suppression. Consistently, a decrease in p21 (a p53 downstream target) and increased p-Rb were detected in cells co-treated with NDRG1-siRNA and PFT-α. |
Annotation:
Loading,please wait...